Study Presented at Heart Rhythm Society Supports Wound-Healing Benefits in Patients Receiving Cardiac Implantable Electronic Devices SILVER SPRING, Md., May 19, 2023 (GLOBE NEWSWIRE) — Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to […]
Tag: CanGaroo
Aziyo Announces FDA 510(k) Submission for CanGaroo® RM, its Next-Generation Biomaterial Envelope Enhanced with Antibiotics
SILVER SPRING, Md., April 04, 2022 (GLOBE NEWSWIRE) — Aziyo Biologics, Inc. (Nasdaq: AZYO), today announced the Company has filed a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for CanGaroo® RM Antibacterial Envelope, its next-generation biomaterial envelope […]
Aziyo Biologics Announces Initiation of De Novo CanGaroo Clinical Study
SILVER SPRING, Md., April 28, 2021 (GLOBE NEWSWIRE) — Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, announced today the initiation of […]
Aziyo Biologics Announces Product Design Completion for its Next Generation CanGaroo® Envelope for Implantable Electronic Devices
SILVER SPRING, Md., Feb. 11, 2021 (GLOBE NEWSWIRE) — Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, announced today product design completion […]
Aziyo Announces CanGaroo Strategic Co-Distribution Agreement with BIOTRONIK US
SILVER SPRING, Md.–(BUSINESS WIRE)–Aziyo Biologics, Inc., a fully integrated regenerative medicine company, today announced that it has entered into a US co-distribution agreement for its CanGaroo® Bio Envelope with BIOTRONIK, Inc., a global leader in cardio- and endovascular medical technology. CanGaroo […]